image credit: Richard Masoner / Flickr

Another one BiTEs the dust as Amgen pauses enrollment for phase 1 bispecific trial

It’s another one gone and another one gone for Amgen, as the pharmaceutical giant reported the latest clinical stoppage for a bispecific T-cell engager, or BiTE, therapy.

Amgen has stopped enrolling acute myeloid leukemia patients in a phase 1 clinical trial of its half-life extended FLT3 BiTE therapy AMG 427. News of the stoppage comes months after Amgen hit pause on a clutch of other BiTE clinical trials.

AMG 427 was moved into a phase 1 study in 2018. Amgen last week updated the listing for the therapy to “active, not recruiting” without providing an explanation for the decision to stop enrolling new patients.

Read More on FierceBiotech